Alpha Cognition Surpasses Expectations with Impressive Growth in 2Q26

Impressive Financial Performance in 2Q26

Alpha Cognition Inc. (NASDAQ: ACOG) has demonstrated substantial progress in the second quarter of 2026, as reported by Stonegate Capital Partners. The company experienced a notable 71% quarter-over-quarter increase in net product revenue, reaching $6.0 million. This growth was driven by a 37% increase in bottles dispensed, totaling 8,294, with June alone accounting for an impressive 2,997 bottles—the strongest month since the launch of its product, ZUNVEYL.

The quarter's achievements are particularly noteworthy given the absence of material stocking benefits and unchanged downstream PBM implementation at approximately 16%. This suggests that the underlying demand and improved commercial execution are key factors contributing to Alpha Cognition's success. The company's management has indicated that the growth momentum has continued into the third quarter of 2026.

Expanding Adoption and Utilization

The demand for ZUNVEYL has not only increased but has also extended its reach across various prescribers and facilities. During the quarter, Alpha Cognition reported 1,347 quarterly prescribers, with 1,024 being repeat prescribers. In total, 1,908 cumulative writers and 1,095 long-term care (LTC) facilities generated prescriptions, indicating a deepening utilization and broadening adoption of the product.

This expansion is occurring despite the fact that broader formulary activation has not yet been realized. The core setup for Alpha Cognition remains promising, with ample white space across homes and physicians, deepening utilization, and the potential for broader PBM implementation to further drive growth.

Strategic Focus on Commercial and R&D Investment

Alpha Cognition continues to balance its commercial investments with a growing evidence base. The company has projected a reduction in its fiscal year 2026 R&D and SG&A guidance to $50 million-$54 million, while still maintaining its target for operating profitability by 2027. Several upcoming milestones, such as the anticipated CONVERGE data in the third quarter of 2026 and ongoing RESOLVE trials, underscore the company's commitment to achieving greater operating leverage.

As Alpha Cognition navigates this trajectory of growth and innovation, the expertise provided by Stonegate Capital Partners plays a pivotal role. Stonegate offers investor relations, equity research, and institutional investor outreach services, supporting public companies like Alpha Cognition in their quest for market leadership.

For further details on the recent developments at Alpha Cognition and to access the full announcement, including downloadable images and bios, interested parties can click here.

Alpha Cognition's impressive performance in 2Q26 is a testament to its strategic execution and robust demand for ZUNVEYL. As the company continues to expand its reach and deepen its market presence, it remains poised for further growth and success in the coming quarters.